ClinicalTrials.gg
RecruitingNCT06570291Updated Jul 16, 2025

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis

A Phase 3 interventional study of Mesenchymal Stem Cells and Sodium Hyaluronate Injection in Knee Osteoarthritis, sponsored by Wuxi Cellular Biopharmaceutical Group Ltd.. Recruiting at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Wuxi Cellular Biopharmaceutical Group Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
7th of 115
520 · median 100
Started
2025
with 9 others
Phase 3
14 of 136
4 open now
Primary completion
2026-12
later than 18 of 31 live
Registered
107th of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 7th largest by planned enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 18 of the 31 other live ones, and was the 107th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Therapy

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who understand and voluntarily sign the consent form before this study;
  2. According to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed;Course of knee osteoarthritis was more than 6 months;
  3. Age: 40-75, males and females;
  4. The subjects' WOMAC score was 24-72
  5. The Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade II / III;
  6. Subjects are generally in good condition and can walk autonomously, except for those who use wheelchairs, walking aids or crutches.

Exclusion criteria

Exclusion Criteria:

  1. The subject may be allergic to the main cell preparation components (B vitamins, amino acids and so on).
  2. The subject received systemic and / or local treatment with autologous and / or allogeneic mesenchymal progenitor cells.
  3. The subject considered obese.
  4. Laboratory test (any item meets): neutrophil absolute number \< 1.0 × 10\^9 / L, count \< 50 × 10\^9 / L, serum albumin \< 30g / L, serum creatinine > upper limit of 1.2 times normal value range, total 、、aspartate aminotransferase > upper limit of 2 times of normal value range.
  5. The subject has diseases or symptoms may affect VAS, WOMAC and so on.
  6. The subject has serious and poorly controlled concomitant diseases, such as (but not limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and endocrine diseases, which may prevent the subjects from participating in the study according to the judgment of the researchers.
  7. The subject has an history malignant tumour.
  8. The subject has connective tissue disease or rheumatoid arthritis、chondropathy、Chondrocalcinosis articularis、 Hemochromatosis、inflammatory arthropathy、avascular necrosis of femoral head、Paget's disease、hemophilic arthropathy、infectional arthritis、Charcot' s disease、villonodular synovitis or synovial chondromatosis.
  9. The subject has severe generalized infectious diseases or local knee infection (including skin and intra-articular infection) in the 3 months prior to this trial.
  10. According to the researchers, the subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.
  11. The subject had any other coagulation dysfunction caused by acute or chronic diseases, according to the judgment of the researchers, this coagulation dysfunction may endanger the safety of patients and / or affect the judgment of knee joint evaluation indicators.
  12. The subject has received arthroscopic surgery or other open surgery related to knee joint operation in the 6 months prior to this trial.
  13. The subject has received other intra-articular injections, including but not limited to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic glucose and so on for KOA in the 3 months preceding the trial.
  14. The subject has received aminoglucose or chondroitin sulfate within 1 month before the treatment.
  15. The subject has used dexamethasone, prednisone, hydrocortisone and other hormones orally / intravenously within 1 month before the treatment.
  16. The subject has attenuated or injection with 1 month before the treatment.
  17. The subject has undergone knee prosthesis or a plan of knee prosthesis within the trial.
  18. The subject has of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on.
  19. The subject tests positive for: , , and treponema pallidum.
  20. The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial.
  21. The subject has participated in any other clinical trial in the 3 months prior to this trial.
  22. The subject (including male subjects) has fertility, sperm donation or egg donation plans during the trial period; the female subject is pregnant, lactating or having a positive pregnancy test.
  23. The subject is legally disabled by reference to the law of the people's Republic of China on the protection of disabled persons (April 2008).
  24. The subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator.
  25. The Kellgren Lawrence grade (X-ray axial position of knee joint) of any knee joint of the subjects was grade IV.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Mesenchymal stem cells

    Drug: Mesenchymal Stem Cells

  • Placebo comparator
    Sodium hyaluronate

    Drug: Sodium Hyaluronate Injection

Interventions

  • DrugMesenchymal Stem Cells

    Allogenic adipose tissue-derived mesenchymal stem cells administrated for intra- articular use

  • DrugSodium Hyaluronate Injection

    Sodium Hyaluronate administrated for intra-articular use

06

What researchers measure

Primary outcomes

  1. WOMAC score

    The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome,will be tested at 48 weeks after the first injection

    Time frame: 48 weeks

  2. MRI quantitative analysis of articular cartilage

    Time frame: 24 weeks

Secondary outcomes

  1. WOMAC Score

    The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome, will be tested at 4、12、24、36、60、72、84 and 104 weeks after the first injection

    Time frame: 4、12、24、36、60、72、84 and 104 weeks

  2. MRI quantitative analysis of articular cartilage (volume change percentage)

    Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、48、104 weeks after the first injection

    Time frame: 12、48、104 weeks

  3. MRI quantitative analysis of articular cartilage (volume change)

    Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 12、24、 48 and 104 weeks after the first injection

    Time frame: 12、24、 48 and 104 weeks

  4. VAS Score

    Visual Analogue Scale/Score;0-10 points;10 points mean the worse outcome,will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection

    Time frame: 4、12、24、36、48、60、72、84、104 weeks

  5. SF-36

    The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points;100 points mean a better outcome, will be tested at 4、12、24、36、48、60、72、84 and 104 weeks after the first injection

    Time frame: 4、12、24、36、48、60、72、84、104 weeks

  6. Whole-Organ Magnetic Resonance Imaging Score

    Whole-Organ Magnetic Resonance Imaging Score(WORMS) of the knee; 0-332points; 332 points means the worst outcome; will be assessed at 12、24、48 and104 weeks

    Time frame: 12、24、48 and 104 weeks

  7. mJSW

    Minimum joint space width (mJSW) of the knee, will be measured at baseline and 104 weeks

    Time frame: 104 weeks

  8. Physical examination

    Height and weight will be tested and combined to report BMI in kg/m\^2at Day 0 and week 1、2、3、4、12、24、36、48、60、72、84、104 weeks

    Time frame: Day 0、week 1、2、3、4、12、24、36、48、60、72、84、104 weeks

  9. Adverse Events and Serious Adverse Events

    AE and SAE, will be assessed within the 104 week time span

    Time frame: Day 0 to 104 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 22 months is close to that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Feb 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570291
Lead sponsor
Wuxi Cellular Biopharmaceutical Group Ltd.
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Feb 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion